Helen Stephenson-Ellis
Corporate Officer/Principal presso Chartered Institute of Personnel & Development
Posizioni attive di Helen Stephenson-Ellis
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| Chartered Institute of Personnel & Development | Corporate Officer/Principal | - | - |
Storia della carriera di Helen Stephenson-Ellis
Precedenti posizioni note di Helen Stephenson-Ellis
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| OXFORD BIOMEDICA PLC | Ufficiale delle Risorse Umane | 03/04/2018 | 01/05/2022 |
| VERNALIS | Ufficiale delle Risorse Umane | - | - |
Medimmune UK Ltd.
 Medimmune UK Ltd. Chemicals: Major DiversifiedProcess Industries Medimmune UK Ltd. manufactures chemical products. The company was founded on October 6, 1999 and is headquartered in Speke, the United Kingdom. | Ufficiale delle Risorse Umane | - | - |
| ASTRAZENECA PLC | Ufficiale delle Risorse Umane | - | - |
Formazione di Helen Stephenson-Ellis
| University of Northumbria | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Regno Unito | 7 |
Posizioni
| Human Resources Officer | 4 |
| Undergraduate Degree | 1 |
| Corporate Officer/Principal | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| OXFORD BIOMEDICA PLC | Health Technology |
| ASTRAZENECA PLC | Health Technology |
| Aziende private | 2 |
|---|---|
Medimmune UK Ltd.
Medimmune UK Ltd. Chemicals: Major DiversifiedProcess Industries Medimmune UK Ltd. manufactures chemical products. The company was founded on October 6, 1999 and is headquartered in Speke, the United Kingdom. | Process Industries |
Ligand UK Ltd.
 Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
